BRAF and colonic neoplasm: 2.3. Mass Spectrometry-Based Sphingolipidomic Analysis Confirms Dysregulation of S1P Metabolism as the Mechanism Underlying Vemurafenib Resistance in BRAF Mutant Colon Cancer Cells